Biocryst Pharmaceuticals Stock Story
| BCRX Stock | USD 4.21 0.17 3.88% |
Slightly above 64% of BioCryst Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding BioCryst Pharmaceuticals suggests that many traders are alarmed. BioCryst Pharmaceuticals' investor sentiment overview provides quick insight into current market opportunities from investing in BioCryst Pharmaceuticals. The current market sentiment, together with BioCryst Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use BioCryst Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
BioCryst Pharmaceuticals stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of BioCryst daily returns and investor perception about the current price of BioCryst Pharmaceuticals as well as its diversification or hedging effects on your existing portfolios.
BioCryst |
Requested story not found. it has been either deleted or moved. View all stories for BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals Latest Timeline
BioCryst Pharmaceuticals is listed for 4.21. About 88.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 1.18. BioCryst Pharmaceuticals had not issued any dividends in recent years.Check out BioCryst Pharmaceuticals Hype Analysis, BioCryst Pharmaceuticals Correlation and BioCryst Pharmaceuticals Performance. For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Complementary Tools for BioCryst Stock analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is BioCryst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioCryst Pharmaceuticals. If investors know BioCryst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioCryst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.18) | Revenue Per Share 1.724 | Quarterly Revenue Growth 0.174 | Return On Assets (0.12) | Return On Equity (19.25) |
The market value of BioCryst Pharmaceuticals is measured differently than its book value, which is the value of BioCryst that is recorded on the company's balance sheet. Investors also form their own opinion of BioCryst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is BioCryst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioCryst Pharmaceuticals' market value can be influenced by many factors that don't directly affect BioCryst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioCryst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioCryst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioCryst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.